ClinicalTrials.gg
RecruitingNCT07480408Updated Nov 20, 2026

Neural Mechanisms of the Sensorymotor Circuit in Sensory Phenomena in OCD

An interventional study of repetitive transcranial magnetic stimulation (rTMS) in Obsessive - Compulsive Disorder, sponsored by Shanghai Mental Health Center. Recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Shanghai Mental Health Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Nov 20, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 28 studies in Obsessive-Compulsive Disorder by Shanghai Mental Health Center — 16 open to participants now, 16 under way, none of them phase 3. Obsessive-Compulsive Disorder · Shanghai Mental Health Center.

Planned enrollment
4th of 25
120 · median 60
Started
2026
with 4 others
No phase
22 of 28
12 open now
Primary completion
2028-12
later than 13 of 15 live
Registered
24th of 28
by date

Among the 28 studies in Obsessive-Compulsive Disorder by Shanghai Mental Health Center, this one is the 4th largest by planned enrollment of the 25 interventional ones that give a count, is one of 5 that started in 2026, is one of 22 with no phase, reaches primary completion later than 13 of the 15 other live ones, and was the 24th registered.

Obsessive-Compulsive Disorder

637 studies on the registry are indexed under Obsessive-Compulsive Disorder; 167 are open to participants now.

Browse Obsessive-Compulsive Disorder studies →

Open to participants now

16 of the 28 studies in Obsessive-Compulsive Disorder by Shanghai Mental Health Center are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

Who these studies take

Of the 120 Obsessive-Compulsive Disorder studies recruiting now, 30 (25%) set no upper age limit and 82 (68%) stop at 75 or younger; 28 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Obsessive-Compulsive Disorder by Shanghai Mental Health Center, or all of them as a file.
02

Study summary

The goal of this clinical study is to investigate the neural mechanisms of abnormal sensory phenomena in patients with Obsessive-Compulsive Disorder and to evaluate whether modulation of the insula-supplementary motor area circuit can improve these symptoms. The study will include adult patients with OCD (with or without sensory phenomena) and healthy volunteers.

The main questions it aims to answer are:

  • Do patients with OCD show abnormal activity in the insula-SMA circuit compared with healthy controls?
  • Is this abnormality associated with the presence and severity of abnormal sensory phenomena?
  • Can low-frequency rTMS targeting the Supplementary Motor Area improve sensory phenomena and obsessive-compulsive symptoms? Researchers will compare an on-line rTMS group (viewing body-focused videos during stimulation) with an off-line rTMS group (resting during stimulation) to evaluate whether task engagement enhances treatment effects.

Participants will:

  • Complete clinical assessments and behavioral tasks.
  • Undergo EEG and fMRI assessments.
  • Receive low-frequency rTMS targeting the Supplementary Motor Area.
  • Repeat assessments after the intervention.
Read the detailed description

Phase 1:

This part adopts a cross-sectional design. A total of 30 patients with Obsessive-Compulsive Disorder with sensory phenomena, 30 OCD patients without sensory phenomena, and 30 healthy controls will be recruited. Clinical assessments will be conducted, including evaluation of the severity of sensory phenomena, as well as obsessive-compulsive, depressive, and anxiety symptoms. Resting-state functional magnetic resonance imaging (fMRI) and electroencephalography (EEG) data will be collected. In addition, during a body-focused video task designed to activate the insula-SMA circuit, task-based fMRI-EEG data will be simultaneously acquired.

Phase 2:

This part adopts a randomized parallel controlled design. Based on the 30 OCD patients with sensory phenomena included in Phase 1, an additional 30 patients will be recruited, resulting in a total of 60 OCD patients with sensory phenomena. After completing baseline clinical scale assessments, behavioral tasks, fMRI, and EEG data collection, participants will be randomly assigned to an on-line group or an off-line group. Both groups will receive low-frequency repetitive transcranial magnetic stimulation (rTMS) targeting the Supplementary Motor Area for six consecutive days, with five sessions per day. In the on-line group, participants will watch body-focused sensory videos during each stimulation session, whereas the off-line group will remain at rest during stimulation. After completion of the intervention, clinical scale assessments, behavioral tasks, and fMRI and EEG data collection will be repeated.

03

Conditions studied

  • Obsessive - Compulsive Disorder

Keywords

  • obsessive-compulsive disorder
  • sensory phenomena
  • supplementary motor area
  • insula
  • neuromodulation
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

OCD with abnormal sensory phenomena

  1. Meet the diagnostic criteria for Obsessive-Compulsive Disorder according to , Fifth Edition.
  2. Aged 18-55 years.
  3. Score ≥16 on the Yale-Brown Obsessive Compulsive Scale, indicating moderate to severe symptoms.
  4. Score >6 on the Sensory Phenomena Scale (SPS), indicating moderate to severe sensory phenomena.
  5. Right-handed.
  6. Either medication-free or on stable medication for at least 8 weeks.

OCD without abnormal sensory phenomena

  1. Meet the diagnostic criteria for Obsessive-Compulsive Disorder according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.
  2. Aged 18-55 years.
  3. Score ≥16 on the Yale-Brown Obsessive Compulsive Scale.
  4. Score ≤6 on the Sensory Phenomena Scale (SPS).
  5. Right-handed.
  6. Either medication-free or on stable medication for at least 8 weeks.

Exclusion criteria

Exclusion criteria

  1. Meeting diagnostic criteria in , Fifth Edition for psychiatric disorders other than OCD or obsessive-compulsive personality disorder.
  2. OCD symptoms so severe that required assessments cannot be completed.
  3. Presence of severe suicidal ideation or high suicide risk.
  4. Pregnant women or women planning pregnancy in the near future.
  5. History of epilepsy or any medical condition that may induce seizures or intracranial hypertension.
  6. to MRI, such as metallic implants.
  7. medical illnesses or abnormal laboratory findings.
  8. Inability to complete study procedures due to severe symptoms, low cognitive functioning, or poor cooperation.

Healthy Controls Inclusion criteria

  1. No current or past psychiatric disorders meeting diagnostic criteria in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.
  2. Aged 18-55 years.
  3. Right-handed. Exclusion criteria

1. Pregnant women or women planning pregnancy in the near future. 2. History of epilepsy or any medical condition that may induce seizures or intracranial hypertension.

3. Presence of severe suicidal ideation or high suicide risk. 4. Contraindications to MRI, such as metallic implants. 5. Clinically significant medical illnesses or abnormal laboratory findings. 6. Inability to complete study procedures due to severe symptoms, low cognitive functioning, or poor cooperation.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    online group

    The on-line group will watch body-focused sensory videos during each rTMS session.

    Device: repetitive transcranial magnetic stimulation (rTMS)

  • Active comparator
    off-line group

    The off-line group will remain at rest during each rTMS sessions.

    Device: repetitive transcranial magnetic stimulation (rTMS)

Interventions

  • Devicerepetitive transcranial magnetic stimulation (rTMS)

    Repetitive transcranial magnetic stimulation (rTMS) will be delivered at 1 Hz with a total of 1,200 pulses per session, administered five times per day for six consecutive days. Target localization will be based on each participant's T1-weighted structural MRI, using a neuronavigation system to establish an individualized head model and identify the Supplementary Motor Area. The stimulation intensity will be set at 110% of the individual resting motor threshold (RMT).

06

What researchers measure

Primary outcomes

  1. Change in Yale-Brown Obsessive Compulsive Scale(Y-BOCS) score

    It assesses the severity of OCD symptoms. The Y-BOCS scale ranges from 0 to 40, with 0 being no symptoms and 40 being severe.

    Time frame: Up to 6 days

Secondary outcomes

  1. Change in Sensory Phenomena Scale (SPS) score

    A semi-structured scale used to assess the presence and severity of sensory phenomena occurring before or during repetitive behaviors. It consists of two parts: a symptom checklist and a severity rating.

    Time frame: Up to 6 days

  2. Change in Beck Depression Inventory(BDI) score

    It consists of 21 items and uses a 0 to 3 severity scale. Total scores range from 0 to 63, with higher scores indicating more severe depression symptoms.

    Time frame: Up to 6 days

  3. Change in Beck Anxiety Inventory (BAI) score

    It is an inventory of anxiety symptoms with 18 items that are rated on a 5-point Likert scale(0 to 4). Total scores range from 0 to 72, with higher scores indicating more severe anxiety symptoms.

    Time frame: Up to 6 days

  4. Change in Perceived Stress Scale(PSS) score

    It is a 10-item, 5-point Likert scale(0 to 4) to measure the degree to which situations in one's life are appraised as stressful.The total score ranges from 0 to 40, with lower total scores representing a better outcome.

    Time frame: Up to 6 days

  5. Change in Obsessive-Compulsive Inventory-Revised (OCI-R) score

    It is a self-report instrument derived from the original 42-item OCI for assessing obsessive-compulsive symptoms. It contains 18 items divided into six subscales, each with three items, assessing six symptom dimensions: washing, obsessing, hoarding, ordering, checking, and neutralizing. Each item is rated on a 5-point scale from 0 to 4, with higher scores indicating more severe symptoms.

    Time frame: Up to 6 days

  6. Change in Obsessive Beliefs Questionnaire (OBQ) score

    This scale consists of 44 items and includes three factors: responsibility/threat estimation, perfectionism/certainty, and importance/control of thoughts.

    Time frame: Up to 6 days

  7. Change in Intolerance Of Uncertainty Scale (IUS-12) score

    This scale consists of 12 items rated on a 5-point Likert scale ranging from "strongly disagree" to "strongly agree." Higher scores indicate lower tolerance of uncertainty. The scale includes two dimensions: inhibitory anxiety and prospective anxiety.

    Time frame: Up to 6 days

  8. Change in Intolerance Of Not Just Right Experiences Questionnaire Revised, (NJRE-Q-R) score

    This scale is used to assess the presence and severity of Not Just Right Experiences in individuals.

    Time frame: Up to 6 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2028, 28 months after the start.

Of 235 non-industry interventional studies with no phase under Obsessive-Compulsive Disorder, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 63. This study's planned 28 months is below that.

Counting every sponsor, half of 238 studies reached it within 43 months; a quarter within 22 and three quarters within 63.

Start moved once since we started tracking on Sep 25, 2026: May 2026 → Aug 2026, on Nov 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2026
First posted
Mar 18, 2026
StartActual
Aug 1, 2026was May 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 20, 2026
Sites
Shanghai Mental Health Center is now Recruiting
Nov 20, 2026
Start date
May 1, 2026→Aug 1, 2026 (actual)
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Not yet recruiting→Recruiting
    Shanghai Mental Health Center is now Recruiting
    Start date May 1, 2026→Aug 1, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07480408
Responsible party
Jiayue CHENG (Principal Investigator, Shanghai Mental Health Center) — Principal investigator
First posted
Mar 18, 2026
Start date
Aug 1, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 20, 2026

Study contacts

Jiayue Cheng, Master
Contact
chengjy_94@163.com
+8602134773503

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion